Maintenance of Long-Term Undetectable Minimal Residual Disease after Combination of Ibrutinib with Abbreviated Chemotherapy in the Icll-07 Filo Trial
61st Annual Meeting and Exposition of the American Society of Hematology . 134 ( Suppl 1 ) : 3038
Poster
voir la publication